Malaria is an unusual complication after hematopoietic stem cell transplantation in non-endemic countries. However, transplant candidates, recipients and donors living in endemic regions frequently report previous episodes of malaria. This fact could represent an important risk for immunosuppressed recipients that could develop severe malaria cases. We report a case of hematopoietic stem cell transplant (HSCT) in which the donor had a history of previous malaria, and close monitoring was performed before and after procedure by parasitological and molecular tests. The donor presented Plasmodium vivax in thick blood smears one month after transplant and was treated according to Brazilian Health Ministry guidelines. The polymerase chain reaction (PCR) was able to detect malaria infection in the donor one week earlier than thick blood film. Even without positive results, the recipient was pre-emptively treated with chloroquine in order to prevent the disease. We highlight the importance of monitoring recipients and donors in transplant procedures with the aim of reducing the risk of malaria transmission.
INTRODUCTION
Malaria is an acute infectious illness caused by Plasmodium falciparum, P. vivax, P. malariae, P. ovale and more recently P. knowlesi was considered the 5 th human plasmodia 19 . Malaria cases due to P. vivax, the most prevalent species in Brazil, can present relapses in the absence of a new infection. It occurs because the hypnozoites, the dormant forms that persist in hepatocytes, can reactivate even after specific treatment and lead to a new malaria case. The dynamics of this mechanism is variable and the period of dormancy can range from one month to two years 11 .
Malaria is an unusual complication after hematopoietic stem cell transplantation in non-endemic countries. However, transplant candidates, recipients and donors living in endemic regions frequently report previous episodes of malaria. In the setting of transplantation, transmission may occur by natural exposure to infected mosquitoes, or as an induced disease, through contaminated blood products or grafts 15, 18 . . Careful investigation of past history of malaria is recommended due to the possibility of persistent disease, that can reach eight years for P. falciparum, 9 three to five years for P. vivax and P. ovale and as long as 44 years for P. malariae 14 . In some non-endemic countries, donors who have lived in malaria areas are recommended to be deferred from donation for three years or receive empiric treatment prior to donating 12, 17 . In endemic regions, a past history of malaria is not an exclusion criterion for donation. As post-transplant immunosuppression may facilitate parasite reactivation, screening before transplant as well as active surveillance with blood tests are strongly recommended. The detection of the parasite by thick blood smear allows species identification and quantification, nevertheless the sensitivity is low, is time consuming and not useful for blood donor screening 10 or transplantation. However, nested PCR is highly sensitive, detecting as few as one parasite per microliter 16 , and therefore suitable for the detection of asymptomatic cases 10, 12 .
Symptomless cases with low parasitemia are due to development of immunity in adults, related to endemicity levels of the different areas 1, 6 . Some recent reports described symptomless infections, with 70% in Mato Grosso 5 and 49.5% in Rondonia 1 , both states in the Brazilian Amazon Region. The high prevalence of asymptomatic infections reported in Brazil is of great concern as the carriers are source of parasites for vectors and also can lead to induced malaria, as reported in a transfusion case, where the recipient died as a consequence of P. malariae infection 8 . The case report described here illustrates the complexity of malaria management after HSCT. Informed consent was obtained from patient's 282 family, and the investigational protocol was approved by the Ethics Committee before the transplant.
CASE REPORT
The HSCT recipient and family, including his brother who was the only compatible donor available, lived in the city of Manaus located in the Amazon rain forest, an endemic region of malaria. While living in the endemic area, nine episodes of malaria have been reported by the donor during his lifetime, being the last one caused by P. vivax in January 2008. Due to the risk of malaria, blood monitoring was proposed to the donor and the HSCT recipient during the first three months after the HSCT. On July 3 rd the donor, living at that time outside of an endemic area, presented with P. vivax malaria and was treated with chloroquine base in a total dose of 25 mg/kg over three days, and primaquine 0.50 mg/kg/ day during seven days. The haemoscopic examination was negative on July 23 th 2008. Despite the complete treatment on September 2 nd 2008, the donor presented symptoms related to malaria. On September 5 th 2008 the donor was diagnosed with P. vivax relapse by thick blood film and was treated as previously.
In October 2008, the transplant candidate, a 6 year-old boy with acute lymphocytic leukemia (ALL) in 3 rd remission was admitted at the Amaral Carvalho Foundation -HSCT Unit to receive an allogeneic peripheral blood stem cells (PBSC) transplant from his 15 year-old brother. The conditioning regimen consisted of cyclophosphamide plus total body irradiation (TBI) and HSCT was performed on October 16 th 2008. Methotrexate and cyclosporine-A (CyA) was introduced for graft-versus-host disease (GVHD) prophylaxis. Neutrophil and platelet engraftment occurred on days 14 and seven after transplant, respectively. On day +10, the recipient presented febrile neutropenia and received 3 rd generation cephalosporin for approximately 20 days. Blood samples from recipient and donor were collected weekly from October 14 th 2008 to December 29 th 2008 for blood smears and PCR tests. Thick blood films were performed and 2 mL of blood were lysed with 1% saponin before DNA extraction with Invisorbâ (Invitek, Berlin) and Brasilica (LGC Biotechnology, Brazil) kits. Nested PCR 16 was accomplished with specific genus and species primers: rPLU5 and rPLU6 for genus and rVIV1/rVIV2, rMAL1/rMAL2 and rFAL1/rFAL2 for species (Invitrogen, Brazil). Fragments were resolved in 1% agarose gel with Blue Green Loading Dye (LGC Biotechnology, Brazil). (Fig 1) . When malaria was diagnosed in the donor, the recipient was on day +26 and asymptomatic. Due to the possible risk of graft-transmitted malaria, the recipient received chloroquine base 25 mg/kg over three days. Primaquine was not given to the recipient because of the absence of the exoerythrocyte cycle in induced malaria cases. The donor was treated with chloroquine base 25 mg/kg over three days and primaquine 0.50 mg/kg/day for seven days, with clinical and parasitological cure. The HSCT recipient did not develop malaria and laboratorial monitoring from patient and donor remained negative during follow-up, until December 29 th 2008 (Table 1) . Unfortunately, the recipient died five months after HSCT due to ALL relapse.
DISCUSSION
Despite of the usual complications of transplants, tropical diseases as malaria, leishmaniasis, Chagas disease and others remain a challenge in endemic countries. Malaria transmission has been reported in kidney 7 , hematopoietic stem cell 12 and multiple tissue transplantation 4 .
The WHO gold standard method for malaria diagnosis is microscopy. It is considered inexpensive and field adapted. Despite being widely 283 used, it requires specifically trained personnel and is not indicated for detection of low parasitemias. Rapid malaria diagnosis tests (RDTs) are unsuitable to detect submicroscopic parasitemia because of their relatively low sensitivity, mainly for non-P. falciparum malaria 2 . However, asymptomatic cases of persistent malaria may occur and more sensitive techniques are necessary to reveal such unsuspected reservoirs of malaria.
This case highlights the importance of sensitive techniques in laboratory surveillance of malaria in patients and donors with epidemiological risk. Molecular detection methods are more sensitive and better adapted to automation allowing objective reading of results. In the present case, PCR could detect Plasmodium DNA in donor sample one week earlier than the blood film, confirming the diagnosis and allowing prophylactic intervention in the recipient. Although nested PCR increases the risk of contamination, the protocol chosen in the present report is well established, species-specific, able to detect one parasite/ microliter and widely adopted in diagnosis and research of malaria 16 . The risk of contamination can be minimized when assays are carried out in well managed and controlled laboratories and with well trained and experienced staff, as was the case in this situation.
Pre-transplant screening of donors and recipients from endemic regions may not be enough to safely rule out persistent malaria. The diagnosis of Plasmodium infection in the donor during the follow up occurred just by chance, since he had no symptoms and also this kind of monitoring is not part of the routine approach in transplant centers in Brazil due to the general unavailability of molecular testing protocols locally. In this case, the monitoring was carried out by the Malaria Reference Center. Since the patient's family was planning to stay for three months in the city where the HSCT centre is located, we opted to monitor the donor who had a recent history of treated malaria. Although control tests were negative at pre-transplant screening, blood films and PCR turned positive during monitoring. In the follow up period, the donor presented with two episodes of malaria without the possibility of external reinfection, since he remained in a no transmission area. Relapses are due to reactivation of hypnozoites from the pre-erythrocytic cycle and can occur despite of complete treatment in a rate that varies from 8% to 24% in Brazil 3 . This mechanism can vary depending on P. vivax strain. As there are no sufficient data comparing primaquine treatment over seven and 14 days, the relapses presented by the HSCT donor could be a result of the short scheme used or failure in the drug absorption. This feature could lead to undetectable parasitemias and absence of symptoms in the beginning of the relapse. Since the HSCT centre city is not a malaria region in Brazil, the infection presented by donor was not a consequence of a new exposure to infected mosquitoes, but rather represent a case of persistent symptomless malaria. Unfortunately, when the diagnosis of malaria in the donor was made, the recipient had already received the graft and prompt treatment was therefore introduced due to the significant risk of malaria. Considering the possibility of malaria transmission reported here, the monitoring of donors and/or HSCT recipients living in endemic areas by both microscopy and molecular tests may represent a safer strategy to prevent graft-transmitted or induced malaria. In the absence of laboratory infrastructure, prophylactic treatment might be indicated to reduce the risk of infection 17 . However, in endemic countries the administration of antimalarials for donors and recipients could lead to unnecessary treatment, especially as some antimalarials present side effects. In our experience, none of six donors or recipients with previous history of malaria developed the disease after follow-up, which varied from one to five years 13 . Even in non-endemic regions, the high frequency of traveling to malaria areas represents a risk of transmission, taking into account the possibility of symptomless cases in non-immune patients, as occurs in P. malariae infections 8 .
In this case, the detection of a relapse due to P. vivax in the donor revealed by thick blood film and confirmed using PCR allowed the prophylactic treatment of the recipient with a safe dosage of the antimalarial drug. Importantly, the follow-up of these cases by multidisciplinary teams enables better decisions, minimizing the risk for the recipient.
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RESUMO

Monitoramento de doadores e receptores provenientes de áreas endêmicas para malária em transplante de células-tronco hematopoiéticas
A malária é complicação incomum após o transplante de células-tronco hematopoiéticas em países endêmicos. No entanto, candidatos a transplantes, receptores e doadores que vivem em regiões endêmicas frequentemente relatam episódios anteriores de malária. Este fato pode representar um risco importante para receptores imunossuprimidos, que podem desenvolver casos de malária grave. Relatamos um caso de transplante de células-tronco hematopoiéticas (TCTH) em que o doador teve história de malária anterior e um monitoramento por meio de exames parasitológicos e moleculares foi realizado antes e após o procedimento. O doador apresentou Plasmodium vivax na gota espessa um mês após o transplante e foi tratado de acordo com as orientações do Ministério da Saúde brasileiro. A reação em cadeia da polimerase (PCR) foi capaz de detectar a infecção por malária no doador uma semana mais cedo do que a gota espessa. Mesmo sem resultados positivos, o receptor foi preventivamente tratado com cloroquina, a fim de prevenir as formas sanguíneas assexuadas. Destacamos a importância do monitoramento de receptores e doadores em procedimentos de transplante, com o objetivo de reduzir o risco de transmissão da malária.
